At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 226 enrolled
Drug / intervention
Nemolizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving Topical Corticosteroids (TCS)
In Brief
A Phase 2 clinical trial evaluating Nemolizumab and Placebo for Atopic Dermatitis. Completed, enrolled 226 participants across 67 sites in 6 countries.
Detailed Summary
Assess the efficacy of several subcutaneous doses of nemolizumab in moderate-to-severe atopic dermatitis (AD) subjects with severe pruritus receiving TCS, who were not adequately controlled with topical treatments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesAustralia, Canada, France, Germany, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartJun 2017
Primary CompletionJul 2018
Study CompletionSep 2018
TodayJul 2026
First PostedApr 4, 2017
Enrollment StartJun 14, 2017
Primary CompletionJul 19, 2018
Study CompletionSep 21, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.2 years ago
Interventions
Nemolizumabdrug
Injection every 4 weeks during 24 weeks (last injection at week 20)
Placebodrug
Injection every 4 weeks during 24 weeks (last injection at week 20)